SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML

Leukemia

Volumn 27, Issue 10, 2013, Pages 2100-2102

  Laborde, R R ^a   Patnaik, M M ^a   Lasho, T L ^a   Finke, C M ^a   Hanson, C A ^a   Knudson, R A ^a   Ketterling, R P ^a   Pardanani, A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; SET BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ATYPICAL CHRONIC MYELOID LEUKEMIA; CANCER PROGNOSIS; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE COURSE; EXOME; FOLLOW UP; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LETTER; LEUKOCYTE COUNT; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTHEMIA;

AGED; CARRIER PROTEINS; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MUTATION; NUCLEAR PROTEINS; PRIMARY MYELOFIBROSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 84885644431     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.97     Document Type: Letter

References (12)

1. Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010; 115: 615-625.
2. Hoischen A, van Bon BW, Gilissen C, Arts P, van Lier B, Steehouwer M et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet 2010; 42: 483-485.
3. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18-24.
4. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013; 27: 1401-1403.
5. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
6. Patnaik MM, Padron E, Laborde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-Defined chronic myelomonocytic leukemia-ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27: 1504-1510.
7. Such E, Cervera J, Costa D, Solé F, Vallesp?́ T, Luno E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375-383.
8. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
9. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113: 1351-1361.
10. Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Minervini A et al. SETBP1 and miR-4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia. J Hematol Oncol 2012; 5: 48.
11. Filges I, Shimojima K, Okamoto N, Röthlisberger B, Weber P, Huber AR et al. Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome. J Med Genet 2011; 48: 117-122.
12. Oakley K, Han Y, Vishwakarma BA, Chu S, Bhatia R, Gudmundsson KO et al. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood 2012; 119: 6099-6108.